Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10745943 | 1.00 | SIGMAR1 (0.78) | SIGMAR1 | |
| SCHEMBL10619052 | 0.88 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL10619043 | 0.88 | SIGMAR1 (1.00) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10621704 | 0.86 | SIGMAR1 (0.98) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10621713 | 0.86 | SIGMAR1 (0.98) | SIGMAR1 | |
| SCHEMBL10619143 | 0.86 | SIGMAR1 (0.87) | SIGMAR1 | |
| SCHEMBL10619147 | 0.86 | SIGMAR1 (0.87) | SIGMAR1 | |
| SCHEMBL10747076 | 0.85 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL10747071 | 0.85 | SIGMAR1 (0.55) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10617701 | 0.85 | SIGMAR1 (0.85) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4663343-A | ANAGESICS, DIURETICS | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| US-7652025-B2 | Remedies for sepsis | TORAY INDUSTRIES, INC. (JP) | 2010-01-26 | — | — | US | disclosed |
| CN-1283317-C | Remedies for sepsis | TORAY INDUSTRIES (JP) | 2006-11-08 | — | — | CN | disclosed |
| US-20040147536-A1 | Remedies for sepsis | TORAY INDUSTRIES, INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| CN-1507356-A | Remedies for sepsis | ������������ʽ���� | 2004-06-23 | — | — | CN | disclosed |
| EP-1402899-A1 | REMEDIES FOR SEPSIS | TORAY INDUSTRIES, INC. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6156769-A | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith | APOLOR CORP. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6048860-A | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith | ADOLOR CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
| US-4663343-A | ANAGESICS, DIURETICS | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147536-A1 | Remedies for sepsis | OPRM1, OPRK1, OPRD1 | SIGMAR1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.